Bristol-Myers Squibb hikes dividend by 9.8%
Bristol-Myers Squibb (BMY) will raise its dividend by 9.8 percent to $0.45 quarterly in the first quarter of 2020. This is the biggest dividend increase by BMY since 2008. The pharmaceutical company just completed the acquisition of biotech company Celgene and has now raised its dividend for 12 consecutive years.
The next quarterly dividend will be payable on February 3, 2020, to stockholders of record at the close of business on January 3, 2020. A new indicated annual dividend rate of $1.80 per share yields 3% at a stock price of $59.95.
Bristol-Myers Squibb Company is is a global specialty biopharmaceutical company. Bristol-Myers is developing new medicines in the following core therapeutic areas: oncology with a priority in certain tumor types; immunoscience with priorities in psoriasis, lupus, RA and inflammatory bowel disease; cardiovascular with a priority in heart disease and; fibrotic disease with priorities in lung and liver. The company's top drugs include Opdivo (infused biologic immuno-oncology treatment) and Eliquis (anticoagulation). In late 2019 Bristol-Myers completed the acquisition of biopharmaceutical company Celgene Corp., combining two companies with valuable overlap in the oncology, immunology, and inflammation therapeutic areas.
The next quarterly dividend will be payable on February 3, 2020, to stockholders of record at the close of business on January 3, 2020. A new indicated annual dividend rate of $1.80 per share yields 3% at a stock price of $59.95.
Bristol-Myers Squibb Company is is a global specialty biopharmaceutical company. Bristol-Myers is developing new medicines in the following core therapeutic areas: oncology with a priority in certain tumor types; immunoscience with priorities in psoriasis, lupus, RA and inflammatory bowel disease; cardiovascular with a priority in heart disease and; fibrotic disease with priorities in lung and liver. The company's top drugs include Opdivo (infused biologic immuno-oncology treatment) and Eliquis (anticoagulation). In late 2019 Bristol-Myers completed the acquisition of biopharmaceutical company Celgene Corp., combining two companies with valuable overlap in the oncology, immunology, and inflammation therapeutic areas.
Comments